Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $104

Benzinga · 1d ago
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $92 to $104.